Business
Tenaya Therapeutics Announces Pricing of Public Offering
SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses. Tenaya intends to u
About this update from Tenaya Therapeutics, Inc.
[{"type":"image","alt":"Tenaya Therapeutics, Inc.","displaySize":"","headline":null,"caption":"Tenaya Therapeutics, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":108,"url":"https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/QJk0bj30LJ12tZdOHYdVGw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE1MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/215b4a449ed1a7a8d8de738f8d3ef7b6","width":300,"height":108}},"lazy":false},{"type":"text","content":"SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, today announced the pricing of its underwritten public offering of 50,000,000 total units for gross proceeds of $60 million prior to deducting underwriting discounts and commissions and offering expenses.","length":480,"tagName":"p"},{"type":"text","content":"Tenaya intends to use the net proceeds from the offering to fund the ongoing and planned development of its clinical and early-stage product candidates, particularly TN-201 and TN-401, and for working capital and other general corporate purposes.","length":246,"tagName":"p"},{"type":"text","content":"The offering is comprised of 50,000,000 units at a public offering price of $1.20 per unit, with each unit consisting of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $1.50 per share. The warrants will be immediately exercisable and will expire five years from the date of issuance. The securities comprising the units are immediately separable and will be issued separately.","length":431,"tagName":"p"},{"type":"text","content":"All of the securities are to be sold by Tenaya. The offering is expected to close on or about December 15, 2025, subject to satisfaction of customary closing conditions.","length":169,"tagName":"p"},{"type":"text","content":"Leerink Partners and Piper Sandler are acting as lead joint book-running managers for the offering. LifeSci Capital also acted as a bookrunning manager.","length":152,"tagName":"p"},{"type":"text","content":"The securities are being offered by Tenaya pursuant to a Registration ...